A phase II study of docetaxel in patients wtth metastatic squamous cell carcinoma of the head and neck

British Journal of Cancer

Volumn 81, Issue 3, 1999, Pages 457-462

  Couteau, C ^a   Chouaki, N ^a   Leyvraz, S ^c   Oulid Aissa, D ^b   Lebecq, A ^b   Domenge, C ^a   Groult, V ^b   Bordessoule, S ^c   Janot, F ^a   De Forni, M ^a   Armand, J P ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b SANOFI   (France)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Docetaxel; Head and neck carcinoma; Phase II trial

Indexed keywords

ANTINEOPLASTIC AGENT; DOCETAXEL;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG CLEARANCE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FLUID RETENTION; HEAD AND NECK CARCINOMA; HUMAN; INFECTION; INTRAVENOUS DRUG ADMINISTRATION; LUNG METASTASIS; MALE; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SKIN TOXICITY; SQUAMOUS CELL CARCINOMA; STOMATITIS; VOMITING;

AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; LIFE TABLES; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; PACLITAXEL; SURVIVAL ANALYSIS; TAXOIDS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 0032872254     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6690715     Document Type: Article

References (29)

1. Aapro M, Zulian G, Alberto P, Bruno R, Oulid-Aissa D and Le Bail N (1992) Phase I and pharmacokinetic study of RP56976 in a new ethanol free formulation. Ann Oncol 3 (abstract 208)
2. Armand JP and Couteau C (1995) Chemotherapy in head and neck treatment. Eur J Cancer 5: 819-822
3. Bissery MC, Guenard D and Gueritte-Voegelein F (1991) Experimental antitumor activity of taxotere, a taxol analogue. Cancer Res 51: 4845-4852
4. Bissett D, Setanoians A, Cassidy J, Graham MA, Chadwick GA, Wilson P, Auzannet V, Le Bail N. Kaye SB and Kerr DJ (1993) Phase I and pharmacokinetic study of taxotere administered as infusion. Cancer Res 53: 523-527
5. Braakhuis BJM, Kagel A and Welters MJP (1994) The growth inhibiting effect of docetaxel (taxotere) in head and neck squamous cell carcinoma xenografts. Cancer Lett 81: 151-154
6. Bruno R, Hille D, Riva A, Vivier N, Bokkel Huinnink W, van Oosterom A, Kayo S, Verweij J, Fossella F, Valero V, Rigas J, Seidman A, Chevallier B, Famoleau P, Burris H, Ravdin P and Sheiner J. (1998) Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol 1: 187-196
7. Burris H, Irvin R, Kuhn J, Kalter S, Smith L, Shaffer D, Fields S, Weiss G, Eckart J, Rodriguez G, Rinaldi D, Wall J, Cook G, Smith S, Vreeland F, Bayssas M, Le Bail N and Von Hoff D (1993) Phase I clinical trial of taxotere administered as either a 2 hour or 6 hour intravenous infusion. J Clin Oncol 11: 950-958
8. Catimel G, Verweij J, Mattijssen V, Hanauska A, Piccart M, Vanders J, Franklin H, Le Bail N and Kaye SB (1994a) Docetaxel (Taxotere): an active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. Ann Oncol 5: 533-537
9. Catimel G, Vermorken JB, Clavel M, DeMulder P, Judsen L Sessa C, Piccart M, Bruntseh U, Verweij J, Wanders J, Franklin H and Kaye SB (1994b) A phase II study of gemcitabine in patients with advanced squamous cell carcinoma of the head and neck. Ann Oncol 5: 543-547
10. Dreyfuss AJ, Clark JR, Norris CM, Rossi RM, Lucarini JW, Busse PM, Poulin MD, Thornhil L, Costello R and Posner MR (1996) Docetaxel an active new drug for squamous cell carcinoma of the head and neck. J Clin Oncol 14: 1672-1678
11. Extra JM, Rousseau F, Bruno R, Clavel M, le Bail N and Marry M (1993) Phase I and pharmacokinetic study of taxotere given as a short intravenous infusion. Cancer Res 53: 1037-1042
12. Forastiere AA, Neuberg D, Taylor IV SG, De Conti R and Adams G (1993) Phase II evaluation of Taxol in advanced head and neck cancer: an eastern cooperative oncology group trial. J Natl Cancer Inst Monogr 15: 181-183
13. Fujii H, Sasaki Y, Ebihara S, Kida Y, Ichikawa G and Kaniyawa S (1955) An early phase II study of docetaxel (taxotere) in patients with head and neck cancer. Proc Am Soc Clin Oncol 14: 298 (abstr 859)
14. Gandia D. Wibault P, Guillot T, Bensmaine A, Armand JP, Marandas P, Luboinski B and Cvitkovic E (1993) Simultaneous chemoradiotherapy as salvage treatment in locoregional recurrences of squamous head and neck cancer. Head Nech 15: 8-15
15. Gebbia V, Testa A, Valenza R, Zerillo G, Restive S, Ingria F, Cannata G and Gebbia N (1993) A pilot study of vinorelbine on a weekly schedule in recurrent and/or metastatic squamous cell carcinoma of the head and neck. Eur J Cancer 29A 9: 1358-1359
16. Gebbia V, Testa A, Cannata G and Gebbia N (1996) Single agent paclitaxel in advanced squamous cell head and neck carcinoma. Ear J Cancer 5: 901-902
17. Landis SH, Murray T, Bolden S and Wingo PH (1998) Cancer statistics, 1998. Cancer J Clin 48: 6-29
18. Pazdur R, Newman RA and Newman BM (1992) Phase I trial of Taxotere: five days schedule. J Natl Cancer Inst 84: 1781 1788
19. Ravdin P, Valero V, Nabholtz JM, Hortobagyi G, Oulid-Aissa D, Riva A, Houver C and Bellet R (1996) Efficacy of 5 day corticosteroid premedication in ameliorating taxotere induced fluid retention. Proc Am Soc Clin Oncol 14: 115 (abstract 124)
20. Recondo G, Armand JP, Tellez-Bernal E, Domenge C, Belehradek M, De Vathaire F, Wibault P, Richard JM and Cvitkovic E (1991) Recurrent and/or metastatic head and neck squamous cell carcinoma: a clinical, univariate, and multivariate analysis of response and survival with cisplatin-based chemotherapy. Laryngoscope 101: 494-501
21. Riou JF, Naudin A and Lavelle F (1992) Effects of taxotere on murine and human tumor cell lines. Biochem Biphys Res Commun 187: 164-170
22. Robert F, Wheeler RH, Molthrop DC, Greene P and Chen S (1994) Phase II study of topotecan in advanced head and neck cancer, identification of an active new agent. Proc Am Soc Clin Oncol 13: 281 (abstract 905)
23. Schornagel JH, Verweij J, De Mulder Ph, Cognetti F, Vermorken JP, Cappeleare, Armand JP, Wildiers j, Clavel M, Kirkpatrick A et al (1992) Phase II trial of 10 ethyl 10 deaza aminopterin, a novel antifolate, in patients with advanced and/or recurrent squamous cell carcinoma of the head and neck. Ann Oncol 3: 223-226
24. Smith RE, Thornton DE and Allen J (1995) A phase II trial of paclitaxel in squarnous cell carcinoma of the head and neck with correlative laboratory studies. Semin Oncol 22: 41-46
25. Tanigawara Y, Sasaki Y, Otsu T, Fujii H, Kashiwura M, Sasaki T, Okuamura K and Taguchi T (1996) Population pharmacokinetics of docetaxel in Japanese patients. Proc Am Soc Clin Oncol 14: 479 (abstract 1518)
26. Tomiak E, Piccart MJ, Kerger J, Lips S. Awada A, De Valeriola D, Ravoet C, Lossignol D, Sculier JP, Auznnnet V, Le Bail N, Bayssas M and Kastersky J (1994) Phase I study of docetaxel administered as 1 hour intravenous infusion on a weekly basis. J Clin Oncol 12: 1458-1467
27. Verweij J (1995) Docetaxel, an interesting new drug for the treatment of head and neck cancer and soft tissue sarcomas. Anti Cancer Drugs, 6: 19-24
28. Vokes EE, Awan AM and Weichselbaum RR (1991) Radiotherapy with concomitant chemotherapy for head and neck cancer. Hematol/Oncol Clin N Am 5: 753 767
29. Vokes EE, Weichselbaum PP, Lippman SM and Hong WK (1993) Head and neck cancer. N Engl J Med 328: 184-194